- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07613996
Impact of Hyperemic State on Angio-IMR Performance
The Impact of Hyperemic State on the Performance of Angiography Derived Indices in Assessing Coronary Microvascular Disease
The goal of this observational study is to evaluate the diagnostic performance of angiography-derived microcirculatory indices (Angio-IMR) in assessing patients with stable angina or suspected coronary artery disease. The main questions it aims to answer are:
How do the numerical values of Angio-IMR from five different software vendors change across three physiological states (resting, sub-hyperemia induced by nitroglycerin, and maximal hyperemia induced by adenosine)? Which physiological state and software algorithm provide the highest diagnostic accuracy (Area Under the Curve, AUC) for diagnosing Coronary Microvascular Disease (CMD) when compared to the gold standard wire-based IMR? Researchers will compare the Angio-IMR results calculated under the three different physiological conditions within the same patient to see how the hyperemic state impacts the performance and consistency of these non-invasive indices.
Participants will:
Undergo standard-of-care coronary angiography and physiological assessment using a pressure wire for index of microvascular resistance (Wire-IMR) as part of their clinical management.
Have their angiographic images captured at three specific time points: at rest, after intracoronary nitroglycerin, and during adenosine-induced maximal hyperemia.
Allow their de-identified imaging and clinical data to be analyzed by an independent core laboratory using five different Angio-IMR software platforms to evaluate microvascular function.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Study Overview and Procedural Protocol
This is a prospective, multi-center, diagnostic accuracy study employing a self-controlled design. All participants will undergo coronary angiography and physiological assessment according to standard clinical indications. During the procedure, specific angiographic images will be systematically captured for the target vessel at three distinct physiological time points:
Resting State: Baseline coronary angiography without any hyperemic agents. Sub-hyperemic State: Following the intracoronary administration of nitroglycerin.
Maximal Hyperemic State: During continuous intracoronary infusion of adenosine to achieve maximal microvascular vasodilation.
Immediately following image acquisition, the reference standard measurement-Wire-IMR-will be performed using a pressure-sensor-equipped guidewire under maximal hyperemia.
Core Laboratory Imaging Analysis and Blinding
All angiographic data will be de-identified and transferred to a centralized, independent Cardiovascular Imaging Core Laboratory at Zhongshan Hospital, Fudan University. The analysis will be conducted as follows:
Software Platforms: Five different commercially available Angio-IMR software platforms (anonymized as A, B, C, D, and E) will be used to calculate microvascular resistance.
Independent Analysis: Five dedicated analysts, each specialized in one specific software platform, will perform the calculations. Each analyst will be blinded to the patients' clinical information, the Wire-IMR gold standard results, and the results from the other four software platforms.
Standardization: A primary researcher, not involved in the software measurements, will pre-define the target vessel segments and measurement frames to ensure consistency across all five software platforms.
Statistical Considerations and Data Management The study aims to determine if the coronary hyperemic state significantly alters the fluid dynamics modeling utilized by Angio-IMR algorithms. AUC will be calculated for each software at each of the three states. A head-to-head comparison of AUCs will be performed using DeLong's test. To maintain data integrity, results from the core laboratory and the clinical centers will remain strictly separated until the final database lock.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Jinying Zhou, MD, PhD
- E-mail: zhou.jinying@zs-hospital.sh.cn
Estude backup de contato
- Nome: Chenguang Li, MD, PhD
- Número de telefone: 021 6404 1990
- E-mail: li.chenguang@zs-hospital.sh.cn
Locais de estudo
-
-
-
Guangzhou, China
- Recrutamento
- The First Affiliated Hospital, Sun Yat-sen University
-
Contato:
- Xun Hu, MD, PhD
- Número de telefone: 020-87608185
- E-mail: hxun@mail.sysu.edu.cn
-
-
Please Select
-
Shanghai, Please Select, China, 200000
- Recrutamento
- Zhongshan Hospital, Fudan University
-
Contato:
- Jinying Zhou, MD, PhD
- Número de telefone: 021 6404 1990
- E-mail: zhou.jinying@zs-hospital.sh.cn
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
The study population consists of adult patients (aged 18 and older) clinically diagnosed with stable angina or suspected coronary artery disease who are scheduled to undergo conventional coronary angiography and invasive physiological assessment.
Participants are prospectively and consecutively recruited from multiple clinical centers in China. The population specifically targets individuals with non-obstructive coronary arteries (stenosis < 50%) or those with moderate stenosis (50%-90%) but preserved epicardial flow (FFR > 0.80), where assessment of coronary microvascular function is clinically indicated to investigate the cause of ischemia.
Descrição
Inclusion Criteria:
- Stable angina or suspected coronary heart disease.
- Scheduled for coronary angiography and physiological assessment.
- Target vessel with stenosis < 50% or 50%-90% with fractional flow reserve (FFR) > 0.80.
- Provided informed consent.
Exclusion Criteria:
- Hemodynamic instability (acute myocardial infarction, cardiogenic shock, severe arrhythmia).
- Contraindications to angiography (e.g., end-stage renal disease).
- Contraindications to adenosine (e.g., severe asthma, high-degree atrial-ventricular block).
- Life expectancy < 1 year or pregnancy.
- Target vessel unsuitable for wire operation (left main lesion, severe tortuosity) or stenosis > 90%.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Single cohort, self-controlled
|
Unlike the reference standard "Wire-IMR," which requires the advancement of a specialized pressure-sensor guidewire into the distal coronary artery, Angio-IMR is a wire-free technology.
It derives microvascular resistance indices purely through computational fluid dynamics (CFD) or specialized mathematical models based on standard coronary angiographic projections.
This eliminates the risk of wire-induced vascular injury or spasm.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Area Under the ROC Curve (AUC)
Prazo: Baseline
|
Comparison of AUC for 5 types of Angio-IMR against Wire-IMR (Gold standard, CMD defined as Wire-IMR ≥ 25) under three states.
|
Baseline
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Diagnostic Accuracy
Prazo: Baseline
|
Sensitivity, specificity, positive predictive value, negative predictive value.
|
Baseline
|
|
Correlation
Prazo: Baseline
|
Pearson/Spearman coefficients between Angio-IMR and Wire-IMR.
|
Baseline
|
|
Agreement
Prazo: Baseline
|
Bland-Altman analysis (Bias and Limits of Agreement).
|
Baseline
|
|
Inter-vendor Agreement
Prazo: Baseline
|
Consistency between different software brands.
|
Baseline
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- B2026-265
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Angiography-derived IMR
-
Peking University First HospitalHangzhou Reprogenix Bioscience, IncAinda não está recrutandoDiabetes MellitusChina
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.RetiradoInsuficiência Cardíaca com Fração de Ejeção Preservada
-
University Hospital, AkershusRescindidoTranstorno bipolar | Psicose | Outros diagnósticos e condiçõesNoruega
-
Consorzio Futuro in RicercaConcluídoAngina Pectoris RefratáriaItália
-
University of WashingtonConcluídoEsquizofrenia | Transtorno bipolar | Doença Mental Grave
-
Imara, Inc.Ativo, não recrutandoAnemia falciformeEstados Unidos, Reino Unido
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.Rescindidoβ talassemiaIsrael, França, Malásia, Peru, Dinamarca, Geórgia, Grécia, Itália, Líbano, Marrocos, Holanda, Tunísia, Reino Unido
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.RescindidoAnemia falciformeEstados Unidos, Omã, Itália, Reino Unido, Líbano, Grécia, Marrocos, Tunísia, Gana, Quênia, Holanda, Senegal, Uganda
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.ConcluídoAnemia falciformeEstados Unidos, Reino Unido
-
University Hospital, AkershusHelse Sor-Ost; RomeriksprosjektetConcluídoTranstornos Mentais, Desordem Mental | Transtornos de Humor | Esquizofrenia | Transtorno bipolar | Transtornos Afetivos, PsicóticosNoruega